FRET-Based Protein Detection Method for Tissue Analysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional immunohistochemistry techniques face challenges with high background noise and low sensitivity due to non-specific binding of antibodies, which hampers accurate protein detection and quantification in tissue samples.
Innovation Solution
A method utilizing a pair of FRET partners, comprising a fluorescent energy donor and acceptor, specifically binds to proteins of interest, reducing background noise through signal amplification and improved signal-to-noise ratio by using two ligands instead of one, and normalizing the FRET signal with a fluorescent DNA marker.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If conventional immunohistochemistry uses a single antibody to detect the protein of interest, then the procedure is simple, but the background noise is high due to non-specific binding
Solution Approach 1:
The patent introduces a second antibody as an intermediary that binds to the first antibody-protein complex. This second antibody is labeled with a fluorescent tag and enables signal amplification while reducing non-specific binding background noise through the FRET mechanism, resolving the contradiction between procedural simplicity and background noise reduction.
Solution Approach 2:
The patent combines two antibodies into a single detection system where the first antibody binds to the target protein and the second antibody binds to the first antibody. This merging of detection functions creates a sandwich complex that amplifies the specific signal while minimizing non-specific binding, thereby reducing background noise while maintaining operational feasibility.
2Productivity
If conventional immunohistochemistry uses a single antibody, then the procedure is rapid, but the sensitivity is low due to lack of signal amplification
Solution Approach 1:
The patent merges two antibodies into a single detection complex where the first antibody provides target specificity and the second antibody provides signal amplification through fluorescent labeling. This combination enables rapid detection while achieving high sensitivity through the amplified fluorescent signal, resolving the contradiction between speed and sensitivity.
Solution Approach 2:
The patent changes the detection parameter from direct antibody binding to FRET-based fluorescent signal detection. By using energy transfer between the fluorescently labeled second antibody and the detection system, the method achieves signal amplification that enhances sensitivity while maintaining the rapid nature of the assay.
3Object-affected harmful factors
If conventional immunohistochemistry uses blocking buffers to reduce non-specific binding, then background noise is reduced, but the procedure requires several additional steps
Solution Approach 1:
The patent uses the second antibody as an intermediary that inherently reduces non-specific binding through the FRET mechanism. This eliminates the need for separate blocking buffer steps, as the dual-antibody FRET system provides both signal amplification and background reduction in a streamlined procedure, resolving the contradiction between background noise reduction and procedural complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly enhances the signal-to-noise ratio, allowing for more accurate and reliable detection and quantification of proteins, particularly in cases where conventional methods fail, such as in HER2 protein detection for breast cancer treatment eligibility.
Implementation Method 1
utilizing a pair of FRET partners, comprising a fluorescent energy donor and acceptor
Implementation Method 2
normalizing the FRET signal with a fluorescent DNA marker
Data Source
Figure 1~2
Figure 3
Figure 4
AI summary
The invention relates to a method for quantifying a protein expressed at the surface of a cell or present in a tissue sample, said method comprising the use of two ligands capable of binding specifically to a domain of said protein.